The prevalence and impact of overlapping Rome IV-diagnosed functional gastrointestinal disorders on somatization, quality of life, and healthcare utilization: A cross-sectional general population study in three countries by Aziz, I. et al.
see related editorial on page x
 INTRODUCTION
 Th e Rome IV consensus documents have recently been 
published to help in the understanding, diagnostic processing, 
and management of functional gastrointestinal disorders (FGIDs) 
( 1,2 ). Th ey defi ne FGIDs as disturbances of the brain–gut axis 
in the absence of organic pathology. Furthermore, in adults the 
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FGIDs now comprise 33 distinct clinical entities which can be 
grouped into one of six anatomical or organ domains: esopha-
geal, gastroduodenal, gallbladder, bowel, anorectal, and centrally 
mediated disorders of GI pain ( 1,2 ).
 FGIDs are common and account for the majority of GI consulta-
tions seen in primary and secondary-care ( 3–17 ). Th ey represent 
a public health burden given their chronic remitting-relapsing 
course, which signifi cantly impacts on an individual’s general 
state of well-being aside from their specifi c GI complaint ( 3,4 ). 
For example, previous studies have shown FGIDs to be associ-
ated with psychological disturbances, somatization, poor quality 
of life (QOL), and increased healthcare interventions such as sur-
gery ( 18–34 ). Moreover, several recent studies have shown that 
FGIDs commonly overlap and are associated with increased extra-
intestinal symptom burden and physician consultations ( 35–38 ). 
However, research on the prevalence of FGIDs and their impact 
on health impairment has been limited, both in the general popu-
lation and in secondary care settings, to evaluations within single 
communities or purely focusing on distinct clinical entities such 
as irritable bowel syndrome (IBS), functional dyspepsia, and 
gastroesophageal refl ux ( 3–38 ). To our knowledge, there have been 
no studies evaluating the epidemiology of all FGIDs comprehen-
sively across multiple community populations to assess how the 
accumulation of FGIDs interacts with measures of general health.
 Th is absence of studies highlights the need for a multi-national 
study and we addressed this issue by using data from a large-
scale, cross-sectional, population-based adult survey across three 
English-speaking countries to help understand the epidemiology 
and clinical associations of Rome IV-diagnosed FGIDs, while using 
subjects without GI disorders (healthy) and those with organic 
GI disease as comparative control groups. We hypothesised that 
Rome IV-diagnosed FGIDs are common and that the accumula-




 Th e comprehensive study questionnaire consisted of two main 
sections: (a) the entire Rome IV diagnostic questionnaire for 
adults that was recently developed and published by the Rome 
Foundation ( 39 ), and (b) an  ad hoc supplemental questionnaire 
designed to address many factors that could be associated with 
FGIDs including demographics, medication, abdominal surgical 
history, doctor-diagnosed organic GI disease, somatization, and 
QOL. Th ese are detailed below.
 1 .  Demographic data—questions enquiring for age, gender, and 
ethnicity. 
 2 .  Medical history—information was sought with regards to 
healthcare visits and we also asked individuals to indicate on 
a checklist if they had a doctor diagnosis of any organic GI 
disease. Th e checklist comprised peptic ulcer disease, celiac 
disease, infl ammatory bowel disease, diverticulitis, and upper 
or lower GI cancer. Furthermore, we enquired for weekly 
intake of medication relevant to GI-related disorders: 
GI-specifi c medication (laxatives, anti-diarrheals, antieme-
tics, antacids, antispasmodics), analgesics (prescribed and 
over-the-counter), complementary medicine (herbal reme-
dies and traditional Chinese medicine), and psychotropics 
(anxiolytics and antidepressants). Finally, subjects were asked 
as to a history of abdominal surgery including cholecystec-
tomy, appendectomy, hysterectomy, bowel resection, or 
any other abdominal surgery (the details of which were not 
further elaborated upon). 
 3 .  Rome IV diagnostic questionnaire ( 39 )—this validated ques-
tionnaire, which presents respondents with 26–86 questions 
depending on applicable skip patterns, has adequate sensiti-
vity and excellent specifi city for the diagnosis of FGIDs, is 
fully understandable to at least 90% of adults, and shows 
good test–retest reliability. It has now been benchmarked 
as the screening tool for FGIDs, their inclusion into clinical 
trials, and for performing epidemiological surveys. For the 
purpose of our study we categorised FGIDs in accordance 
with the six-region division of these disorders in the Rome 
diagnostic system, i.e., into esophageal, gastroduodenal, 
gallbladder, bowel, anorectal, and centrally mediated dis-
orders of GI pain. 
 4 .  Patient health questionnaire (PHQ)-12 somatization score 
( 40,41 )—the PHQ-12 is a modifi ed version of the widely 
used PHQ-15 somatization questionnaire that excludes the 
three GI symptoms (nausea, abdominal pain, altered bowel 
habit), as these are likely to be directly related to FGIDs. 
As a result, the PHQ-12 only records bothersome non-GI 
symptoms over the past month. Th e 12 symptoms assessed 
are back pain, limb pain, headaches, chest pain, dizziness, 
fainting spells, palpitations, breathlessness, menstrual 
cramps, dyspareunia, insomnia, and lethargy. Subjects were 
asked to rate how much they had been troubled by these 
12 symptoms over the last four weeks as 0 (“not bothered 
at all”), 1 (“bothered a little”), or 2 (“bothered a lot”). Th e 
PHQ-12 responses can be used to calculate the number of 
sites reporting somatic symptoms and the overall severity 
of somatic symptoms (PHQ-12 somatization score). Higher 
scores represent greater somatization. 
 5 .  Short form (SF)-8 score ( 42 )—this is a validated question-
naire used in large scale epidemiological studies to assess 
general health-related QOL over the past month. Th e eight 
items enquire about physical functioning, physical role, 
bodily pain, general health perceptions, vitality, social func-
tioning, emotional role, and mental health. Th ese can then 
be aggregated to form a physical component score (PCS) 
and a mental component score, which are normalised to the 
general population that has a mean score of 50 ( 42 ). A high 
PCS or mental component score represents better QOL, 
whereas low scores represent poorer QOL. 
 Questionnaire distribution and completion
 Qualtrics (Provo, UT, USA), a global market survey company, 
was commissioned in the year 2015 to provide a nationally 
representative general population sample of adults from three 
English-speaking countries; the USA, Canada, and UK. Based on 
an estimated prevalence of the major functional GI disorders of 
5–10%, a sample size of 2,000 individuals/country was deemed to 
be adequate for the planned analyses. Th e  individuals recruited 
were from those who had already registered to participate in 
various surveys, such as opinion polls and health studies. Partici-
pants received points from Qualtrics including an opportunity to 
receive shopping credits; no monetary compensation or gift  was 
made. Quota-based sampling was used to ensure equal propor-
tion of sex (50:50), age groups (40% aged 19–39, 40% aged 40–64, 
and 20% aged 65 and older), and education level (30% maxi-
mum with >16 years of formal education) across the countries. 
Subjects were invited to complete a “health survey”. In order to 
avoid selection bias, no information was given to indicate that the 
survey purpose was to examine GI symptoms. All patients read 
an online consent form and electronically accepted study enrol-
ment, aft er which they completed the survey. Th e median com-
pletion time was 19 min with multiple quality assurance methods 
built into the survey to minimise bias and poor quality reporting. 
Th ese included allowing only one response from each computer 
device and excluding respondents who failed two attention-test 
questions or were excessively inconsistent on three GI diagnostic 
questions that were presented twice in the survey specifi cally to 
test consistency of symptom reporting.
    Statistics
  Statistical analysis was carried out using SPSS version 21.0 soft -
ware (SPSS, Chicago, IL, USA), with signifi cance set at a  P -value 
of <0.05. Th ere were no missing data because the online question-
naire required participants to complete each applicable question 
before being allowed to move onto the next step. Categorical vari-
ables were summarized by descriptive statistics, including total 
numbers and percentages, with comparisons between groups 
performed using the chi-square test. Continuous variables were 
summarized by mean and standard deviation, with diff erences 
between multiple independent groups assessed using the one-way 
analysis of variance.  Post hoc pair-wise comparisons were per-
formed using Bonferroni correction.
  Our hypothesis that the accumulation of overlapping FGIDs will 
be associated with worsening ill-health (somatization, QOL, medi-
cation use, and surgical interventions) was assessed using analysis 
of variance with linear contrast analysis to look for a linear trend, 
with eff ect size demonstrated as partial eta squared ( η 2 ); small to 
medium eff ects 0.047–0.11, and large eff ects >0.11 ( 43 ). Finally, the 
risk of having undergone specifi c types of abdominal surgery with 
accumulating FGIDs was determined using odds ratios (OR) and 
95% confi dence intervals (95% C.I.), with healthy subjects serving 
as the control reference.
     RESULTS
   Survey population characteristics
 Th e  survey was completed by 6,300 individuals, of which there 
were 2,100 from each of the three countries. Th ere were 
369 
(5.9%) inconsistent responders who were excluded from analy-
sis, leaving responses from 5,931 individuals in the analysis data 
set; 1,949 from USA, 1988 from Canada, and 1,994 from UK. As 
shown in  Supplementary Table 1A–C , the geographical distribu-
tion of subjects in our sample closely matched the relative popula-
tion distribution within each country (by state, province/territory, 
or government region). Th e only signifi cant exception was under-
representation of subjects from Quebec in the Canadian sample, 
owing to the fact that 84% of Quebec speaks French as their pri-
mary language, whereas the survey could only be completed in 
English. Comparison of age decade distribution of the samples 
with the national populations of the three countries is shown in 
 Supplementary Table 2A–D . All age decades in the sample had 
suffi  cient numbers to represent their respective populations, and 
the age group of 70 years and older amounted to one-tenth of the 
total sample with >500 individuals in the combined three-country 
sample.
 Th e characteristics of the 5,931 subjects are shown in  Table 1 . 
Th e mean age in the total study sample was 47.4 years, with 49.2% 
being female and 72% of white ethnicity. Th e use of medication 
was reported by 48.3%, which comprised analgesics (29.3%), GI-
specifi c medication (25.5%), psychotropics (16.7%), and comple-
mentary medicine (7.2%). A history of abdominal surgery was 
reported by 25.2%, most commonly appendectomy (10.2%), chol-
ecystectomy (8%), and hysterectomy (6.3%). Th e PHQ-12 score in 
the general population was 4.8, with the norm-based SF-8 QOL 
physical and mental component scores recording similarly at ~49 
points.
 The prevalence of gastrointestinal diseases
 In 57.7% ( n =3421) no GI disorder was discernible on the Rome 
diagnostic questionnaire or reported by the subjects, and these 
individuals were subsequently classed as non-GI (healthy) con-
trols. As shown in  Table 2 , a doctor-diagnosis of organic GI 
disease was reported by 7.2% ( n =427) of the study sample, and 
those subjects were classed as organic GI controls. Diverticulitis 
(2.9%) predominated in this subgroup, followed by peptic ulcer 
disease (1.7%), infl ammatory bowel disease (1.4%), and GI can-
cer (1.1%), with celiac disease (0.6%) being the least common. 
Rome IV symptom criteria for any FGID, and without organic 
GI disease, were met by 35.1% ( n =2083) of the subjects, and 
this was similar across the three countries;  P =0.25. In the entire 
population sample the functional bowel disorders predominated 
at 28.1% ( n =1665), followed by gastroduodenal (10.6%,  n =627), 
anorectal (7.4%,  n =440), and esophageal (7.0%,  n =414) dis-
orders. Gallbladder disorders (0.2%,  n =10) were rare and only one 
person fulfi lled criteria for a centrally mediated disorder of GI 
pain (0.02%); as a result these two FGID groups were excluded 
from further analysis.
 With regards to diff erences between the three countries the 
Canadian cohort were signifi cantly more likely to have peptic ulcer 
disease compared with the UK. In contrast, functional gastroduo-
denal disorders were signifi cantly more prevalent in the US cohort 
(12.3%) than in subjects from Canada (9.8%) or UK (9.7%). Th e 
prevalence of functional esophageal disorders was also highest in 
those from the USA (8.4%), which was non-signifi cant compared 
with Canada (6.8%) but signifi cantly greater than the UK (5.8%). 
Th e  prevalence o f f unctional b owel a nd a norectal d isorders w as 
similar across the countries.
    Comparison of subjects with FGIDs against non-GI and organic 
GI disease controls
   Table 1  compares the FGIDs group against organic GI 
disease and non-GI (healthy) controls. Th e FGIDs group was 
younger, and more female predominant, whereas those with 
organic GI diseases were older, compared with the non-GI 
controls. There 
was also a signifi cant stepwise increase from healthy controls to 
FGIDs and organic GI disease subjects with regard to frequency 
of healthcare visits, and mean number of medical and surgical 
interventions. However, it was noteworthy that only rates of chol-
ecystectomy and hysterectomy, but not appendectomy or bowel 
resection, were signifi cantly higher in subjects with FGIDs com-
pared with non-GI controls.
 Both FGID and organic GI disease subjects scored signifi cantly 
worse in somatization and QOL compared with non-GI controls. 
As there was a higher female prevalence among FGIDs compared 
to non-GI (healthy) controls, we evaluated whether removing 
 Table 1 .  The overall characteristics and comparison between FGID subjects against healthy and organic GI disease controls 
 Overall 
( n =5931) 
 Healthy/non-GI 
( n =3,421; 57.7%) 
 FGIDs 
( n =2,083; 35.1%) 
 Organic GI disease 
( n =427; 7.2%) 
 P -value a 
 Demographics 
 Mean-age (s.d.)  47.4 (17.1)  47.7 (17.2)  45.1 (16.5)  57.1 (15.8)  <0.001 b , c , d 
 Female  2,918 (49.2%)  1,459 (42.6%)  1,236 (59.3%)  223 (52.2%)  <0.001 b , c , d 
 White ethnicity  4,271 (72%)  2,403 (70.2%)  1,529 (73.4%)  339 (79.4%)  <0.001 b , c , d 
 Healthcare utilization 
More than once yearly healthcare visits  3,407 (57.4%)  1,684 (49.2%)  1,392 (66.8%)  331 (77.5%)  <0.001 b , c , d 
Medication taken at least once weekly 
  GI-specifi c medication  1,512 (25.5%)  476 (13.9%)  817 (39.2%)  219 (51.3%)  <0.001 b , c , d 
  Analgesics  1,737 (29.3%)  669 (19.6%)  871 (41.8%)  197 (46.1%)  <0.001 b , c 
  Psychotropic medicine  993 (16.7%)  340 (9.9%)  535 (25.7%)  118 (27.6%)  <0.001 b , c 
  Complementary medicine  426 (7.2%)  178 (5.2%)  196 (9.4%)  52 (12.2%)  <0.001 b , c 
Any of the above medication  2,864 (48.3%)  1,189 (34.8%)  1,373 (65.9%)  302 (70.7%)  <0.001 b , c 
Mean number of medication, max=11 (s.d.)  1.05 (1.5)  0.6 (1.0)  1.6 (1.7)  2 (2)  <0.001 b , c , d 
 Previous surgery 
  Cholecystectomy  472 (8%)  196 (5.7%)  204 (9.8%)  72 (16.9%)  <0.001 b , c , d 
  Hysterectomy  372 (6.3%)  136 (4%)  161 (7.7%)  75 (17.6%)  <0.001 b , c , d 
  Appendectomy  603 (10.2%)  295 (8.6%)  218 (10.5%)  90 (21.1%)  <0.001 c , d 
  Bowel resection  108 (1.8%)  24 (0.7%)  16 (0.8%)  68 (15.9%)  <0.001 c , d 
Other abdominal or pelvic surgery  460 (7.8%)  176 (5.1%)  216 (10.4%)  68 (15.9%)  <0.001 b , c , d 
Any of the above abdominal surgeries  1492 (25.2%)  659 (19.3%)  606 (29.1%)  227 (53.2%)  <0.001 b , c , d 
Mean number of abdominal surgeries, max=5 (s.d.)  0.34 (0.7)  0.24 (0.55)  0.39 (0.7)  0.9 (1)  <0.001 b , c , d 
 Symptom scores 
Mean PHQ-12 somatization score (s.d.)  4.8 (3.8)  3.3 (3)  6.8 (3.9)  6.3 (4.3)  <0.001 b , c , d 
Mean number of somatic symptoms (s.d.)  3.7 (2.6)  2.8 (2.2)  5.1 (2.4)  4.7 (2.7)  <0.001 b , c , d 
Mean norm-based SF-8 quality of life (s.d.) 
Physical component score, PCS  49.2 (9.8)  52 (7.8)  45.7 (10.7)  43.8 (11.2)  <0.001 b , c , d 
Mental component score, MCS  49 (10.9)  52.1 (8.8)  44.1 (12.1)  47.9 (11.3)  <0.001 b , c , d 
 FGIDs, functional gastrointestinal disorders; GI, gastrointestinal; PCS, physical component score; PHQ, patient health questionnaire; MCS, mental component score. 
Note: Superscript letters are signifi cantly different at a  P <0.05. 
 a P -value is difference between non-GI, FGIDs and organic GI disease subjects. 
 b Indicates the FGID group is signifi cantly different compared with healthy group. 
 c Indicates the organic group is signifi cantly different compared with healthy group. 
 d Indicates organic group is signifi cantly different compared with FGID group. 
 Table 3 , showing increasing rates of cholecystectomy and hysterec-
tomy, but not appendectomy or bowel resection. Th e accumulation 
of FGID-aff ected GI regions was also associated with increased 
frequency of more than once yearly health care visits, ranging from 
menstrual cramps and dyspareunia from the somatisation analysis 
would aff ect the diff erence seen between the groups, but somati-
sation still remained signifi cantly greater in subjects with FGIDs.
    Presence of FGIDs in multiple GI regions and its effect on 
health impairment
I  n the 2,083 subjects meeting Rome criteria for FGIDs, 64% 
( n =1341) had one GI region aff ected by a FGID and 36% ( n =742) 
had more than one aff e cted G I r egion; 2 4% (  n = 493) h ad t wo 
aff ected regions, 8% ( n =166) had three, and 4% ( n =83) had symp-
toms meeting FGID criteria in four GI regions ( Figure 1 ). Th i s 
gave a total of 3,157 aff ected GI regions in 2083 FGID subjects, 
averaging 1.5 GI regions per affl  icted subject.
 Furthermore, Figure 2 depicts in detail the overlapping relation-
ship between the FGIDs. It reveals a complex interaction with mul-
tiple overlapping permutations between the FGIDs. In summary, 
the 64% of subjects with an isolated FGID reported bowel (47.8%), 
gastroduodenal (9.2%), esophageal (4.7%), and anorectal (2.7%) 
disorders. In the remaining 36% with overlapping FGIDs, the most 
frequent overlap was between bowel-anorectal (9.1%), bowel-
gastroduodenal (7.5%) and bowel-esophageal (4.2%). Th e  l east 
frequent overlap was seen between anorectal-esophageal (0.1%).
  Linear contrast analysis demonstrated that with the 
increase in overlapping FGIDs there was a signifi cant linear 
trend asso-ciated with higher PHQ-12 somatization scores, 
more somatic symptoms, poorer mental and physical SF-8 
QOL scores, greater consumption of medical therapies, and a 
higher prevalence of sur-gical interventions ( Figure 3 ). Th e risk 
of specifi c types of abdomi-nal surgery with accumulating 
spread of FGIDs is reported in 
 Table 2 .  Prevalence of gastrointestinal disorders within the adult population in the USA, Canada, and UK 
 Overall 
 n =5931 
 United States 
 n =1949 
 Canada 
 n =1988 
 United Kingdom 
 n =1994 
 P -value a 
 Organic gastrointestinal disease  427 (7.2%)  149 (7.6%)  155 (7.8%)  123 (6.2%)  0.1 
 Celiac disease  37 (0.6%)  17 (0.9%)  11 (0.6%)  9 (0.5%)  0.2 
Infl ammatory bowel disease  82 (1.4%)  24 (1.2%)  33 (1.7%)  25 (1.3%)  0.4 
 Gastrointestinal cancer  64 (1.1%)  22 (1.1%)  21 (1.1%)  21 (1.1%)  1.0 
Peptic ulcer disease  102 (1.7%)  32 (1.6%)  51 (2.6%)  19 (1%)  <0.001 b 
 Diverticulitis  171 (2.9%)  69 (3.5%)  50 (2.5%)  52 (2.6%)  0.1 
 Functional gastrointestinal disorders  2083 (35.1%)  683 (35%)  724 (36.4%)  676 (33.9%)  0.25 
 Esophageal Disorders  414 (7%)  164 (8.4%)  135 (6.8%)  115 (5.8%)  0.01 c 
 Gastroduodenal disorders  627 (10.6%)  240 (12.3%)  194 (9.8%)  193 (9.7%)  0.01 c , d 
 Gallbladder disorders  10 (0.2%)  7 (0.4%)  2 (0.1%)  1 (0.1%)  0.04 
Centrally mediated disorders of GI pain  1 (0.02%)  1 (0.05%)  0 (0%)  0 (0%)  0.4 
 Bowel disorders  1665 (28.1%)  534 (27.4%)  583 (29.3%)  548 (27.5%)  0.3 
 Anorectal disorders  440 (7.4%)  148 (7.6%)  150 (7.5%)  142 (7.1%)  0.8 
 Note: superscript letters are signifi cantly different at a  P <0.05. 
 a P -value is difference between countries. 
 b Indicates Canada is signifi cantly different compared with UK. 
 c Indicates the USA is signifi cantly different compared with UK. 
















 Figure 1 .  The relationship between number of people with FGIDs and 
number of affected GI regions. There are 2083 people who fulfi lled criteria 
for FGIDs with the total number of affected GI regions being 3157. The mean 
ratio of affected GI segments per FGID subject was 1.5 to 1 (3157/2083). 
49.2% for no FGIDs, 64.4% for one region with FGID, 68.8% for 
two regions, 74.1% for three regions, and 79.5% for four regions 
( P <0.001).
  Finally, we also compared the eff e ct o f a ccumulating F GID-
aff e cted r egions o n i ll-health w ith o rganic G I d isease c ontrols. 
Individuals with FGID in only one region of their GI tract had 
similar PHQ-12 somatization scores and number of somatic symp-
toms as seen in organic GI disease subjects ( P =0.56 and  P =0.94, 
respectively), but the presence of ≥2 regions with FGIDs led to 
higher somatization scores ( P <0.001). In terms of mental compo-
nent score SF8-QOL, the presence of one ( P =0.003) or more FGID 
regions ( P <0.001) led to worse scores than organic GI disease sub-
jects. Further, presence of FGID in only one region was associated 
with better PCS-QOL than organic GI disease subjects ( P =0.003), 
FGID in two regions was associated with similar scores ( P =1.0), 
but subjects with three ( P =0.005) and four FGID aff ected regions 
( P <0.001) had worse PCS–QOL scores than organic GI disease 
subjects. For medication use, subjects with FGID in one region 
had less medication use than organic GI diseases ( P <0.001), those 
with two FGID regions had equivalent use ( P =0.9), and those 
with three ( P =0.01) and four FGID aff ected regions ( P <0.001) had 
greater medication use. With regards to surgery, individuals with 
FGIDs in ≤3 regions had lower overall surgical interventions than 
organic GI disease subjects ( P <0.001) and those with four aff ected 
regions had similar rates ( P =0.29). In summary, other than sur-
gery, the increasing spread of FGIDs across multiple GI regions 
led to health impairment exceeding that reported by organic GI 
disease subjects.
     DISCUSSION
  Having used the recently published Rome IV diagnostic ques-
tionnaire we present the fi r st l arge-scale m ulti-national s tudy 
evaluating the total prevalence of FGIDs and their overlap 
or spread across GI regions in the general adult population. 
More over, we compare FGID subjects with both healthy and 
organic GI disease controls, whilst also determining the eff ect 
of overlapping FGIDs on somatization, QOL, and healthcare 
utilization. Th is has allowed novel insights to be gained into the 
magnitude of FGIDs and their interaction with general health 
and wellbeing.
 We identifi ed t hat a  t hird (35%) of t he general adult p opula-
tion from the USA, Canada, and UK fulfi ls diagnostic criteria for 
Rome IV FGIDs, with bowel disorders representing the majority 
of these cases, followed by gastroduodenal, anorectal, and esoph-
ageal disorders. In contrast, gallbladder disorders are infrequent 
and centrally mediated disorders of GI pain exceedingly rare. We 
have also shown that the FGIDs group (along with organic GI 
disease subjects) have worse somatization scores, poorer QOL, 
and excess healthcare utilization compared with healthy controls. 
Furthermore, we note that in FGID subjects, symptoms qualify-
ing for FGID diagnosis are present in 1.5 GI regions on average; 
this is owing to more than a third of FGID subjects having mul-
tiple aff ected GI regions, with the most f requent overlaps being 
co-existence of symptoms of bowel disorders with those of ano-
rectal, gastroduodenal, and esophageal disorders. Moreover, the 
diagnosis of FGIDs in multiple GI regions was associated with 
increasing extra-intestinal symptom scores, medication use and 
surgical intervention which, other than surgery, also exceeded 
those reported by organic GI disease subjects. Th e se fi  ndings are 
consistent with the recent literature, although studies in this fi eld 
are limited to community-based studies evaluating the eff ect of 
few overlapping FGIDs (i.e., IBS/functional dyspepsia/gastroe-
sophageal refl ux) on either somatization, QOL, symptom-burden 
and consultation behavior, or a secondary care study evaluating 
multiple FGIDs and showing that their step-wise accumulation 
leads to increasing anxiety and depression ( 35–38 ). Our study 
augments these fi n dings b y p roviding a n o verarching p erspec-
tive of all FGIDs and the eff ect of their overlap on multiple health 
parameters (including for the fi r st t ime, s urgery), w hile u sing 
a control group. As such, our fi n dings h ave i mportant i mplica-
tions in that they highlight the need for future planning of clinical 
service and research in the fi eld of FGIDs. In the United States, 
three of the leading six GI diagnoses at ambulatory care visits are 
accounted for by motility or functional disorders; refl ux symp-
toms, constipation, and IBS ( 44 ). Moreover, FGIDs incur signifi -
cant costs to patients, healthcare systems (both for GI and non-GI 
related care) and society through work absenteeism and presen-
teeism. In 2004, the direct and indirect costs for refl ux symptoms 
and all other FGIDs combined amounted to $16 billion in the 
USA, which was almost a tenth of the total expenditure for all 
digestive diseases ( 44 ). Factors that are associated with healthcare 
seeking behavior in FGIDs include poor QOL and psychological 
symptoms ( 45 ). Hence, our results indicating a signifi cant adverse 
























 Figure 2 .  Venn diagram showing the overlap between FGIDs ( n =2,083). 
Note: (i) Numbers not shown in fi gure; the overlap between bowel-oesoph-
ageal, which was 4.2%, and gastroduodenal-anorectal, which was 0.9%. 
(ii) The areas within the diagram are not quite proportional to the numbers.
(iii) Data for gallbladder ( n =10) and centrally mediated disorders of GI
pain ( n =1) not presented as small numbers.
distinguish between isolated and multi-region FGIDs, to help 
toward the understanding of pathophysiological mechanisms and 
the optimization of treatment. In view of the widespread symp-
tomatology incurred by subjects with overlapping FGIDS it may 
that individuals suff ering from such broad affl  iction can 
be expected to have greater medical care needs and perhaps 
diff er-ent treatment requirements compared with other FGID 














































































































































Number of GI regions with a FGID
ANOVA p< 0.001, partial η2=0.25 ANOVA p< 0.001, partial η2=0.22
ANOVA p< 0.001, partial η2=0.15 ANOVA p< 0.001, partial η2=0.13
ANOVA < 0.001, partial η2=0.2 ANOVA p< 0.001, partial η2=0.02
Two Three Four
None One
Mean number of GI regions with a FGID
Two Three Four
None One
Number of GI regions with a FGID
Two Three Four None One
Number of GI regions with a FGID
Two Three Four
None One
Number of GI regions with a FGID
Two Three Four
None One
Number of GI regions with a FGID
Two Three Four
 Figure 3 .  Linear relationship between number of GI regions affected with FGIDs and somatization, quality of life, medication use, and surgeries. 
be speculated that their disease etiology is centrally, as opposed 
to peripherally, mediated. An initial randomized controlled 
trial found subjects with high levels of somatization and severe 
IBS to show the greatest degree of benefi t  f rom centrally acting 
desensitizing treatments (such as antidepressants and behavioral 
therapies) compared with standard treatment modalities ( 46 ). 
However, given the general paucity of data further randomized 
controlled trials are needed.
  With regards to the increased surgical rates we observed in sub-
jects with FGIDs, the reasons are unclear. It is a fi nding that is in 
agreement with multiple previous studies, and various explana-
tions have been proposed. Th ese include misdiagnosis of FGIDs 
resulting in a surgical operation or, conversely, FGID symptoms 
occurring as a consequence of an operation ( 24–34 ). For exam-
ple, recent insights demonstrate that gut visceral hypersensitivity 
is frequently responsible for the disproportionate pain experienced 
by patients with suspected endometriosis, in particular those who 
have normal to minimal laparoscopic fi n dings a nd m ay h ave 
otherwise gone on to have a hysterectomy ( 47 ). On the other hand, 
a cholecystectomy can lead to bile acid malabsorption mimick-
ing functional diarrhea or diarrhea predominant IBS ( 48 ). Th e se 
are plausible reasons given that the increased risk of surgery 
in FGIDs tracked only for hysterectomy and cholecystectomy, 
but not appendectomy or bowel resection where surgery would 
generally be predicated on objective indications. Our study did not 
assess the temporal relationship between fi rst onset of symptoms 
of FGIDs and surgery, but another plausible hypothesis worthy of 
consideration, given the associated somatization, is that surgery 
is being undertaken in co-existing viscerally sensitive somatic 
sites. For instance, period pains and dyspareunia are commonly 
reported in IBS patients potentially prompting hysterectomies 
( 49–51 ). Another somatic symptom is back pain and there is evi-
dence to show a 50% increase in back surgery for subjects with IBS 
compared with healthy controls ( 26 ). Unfortunately, when subjects 
have undergone such surgical interventions the resected specimen 
is generally normal and moreover patients do not report a clinical 
improvement ( 52,53 ).
  A key strength of our study is that it is the fi rst one to sample 
the prevalence and impact of all FGIDs, using the validated 
new Rome IV diagnostic questionnaire across a large number 
of individuals in the general adult population in three English-
speaking countries. In contrast, previous studies have been lim-
ited to evaluating the prevalence and eff ect of FGIDs within single 
communities or focusing on distinct clinical entities such as IBS 
and functional dyspepsia ( 3–38 ). In some countries the Rome III 
diagnostic questionnaire was modifi ed and translated into other 
languages without validation ( 15,16 ). Hence, we believe that our 
study provides confi d ence i n t he a ccuracy and c onsistent i nter-
pretation of the Rome IV questionnaire thereby allowing the 
results to be generalized.
  Nevertheless, our study does have several limitations. First, this 
data set does not cover the epidemiology of FGIDs globally. At the 
time the survey was conducted, no professional translations of the 
new Rome IV diagnostic questionnaire had yet been completed, 


































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































we also introduced the survey as one of general health and not 
GI-related. Finally, data quality checks were incorporated to 
ensure no missing data and that any inconsistent responders 
were eliminated from the fi nal analysis. We therefore believe 
that we undertook necessary measures to counteract potential 
bias associated with online surveys and provide a representative 
epidemiological profi le.
 In conclusion, roughly a third of the general adult population 
fulfi ls diagnostic criteria for Rome IV FGIDs. Furthermore, in a 
third of this subset multiple regions of the GI tract are involved and 
this more widespread presence of FGID symptoms is associated 
with increased somatization, poorer QOL, and greater healthcare 
utilization. Th ese fi ndings have important public health implica-
tions as awareness of the epidemiological scale of FGIDs and the 
detrimental eff ect on general health and well-being, resulting from 
the co-existence of FGIDs in multiple GI regions will aid clini-
cal service and research provision planning, and underlines the 
importance of comprehensive FGID assessment of patients.
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our choice of countries to be included and also meant that 
in Canada, only individuals who were fl u ent i n E nglish c ould 
participate, which may have excluded as many as one in fi ve Cana-
dian adults. Generalizability of our fi ndings to non-English speak-
ing populations is unknown at this point, but will be elucidated by 
the fi ndings of a Global FGID survey with comparable methodol-
ogy which is now under way.
  A second limitation was that despite the overall prevalence of 
FGIDs being similar across the countries, we noted that people 
in the USA are more likely to have functional upper GI disorders, 
and we did not collect information that could explain this dif-
ference. Other groups have noted that global prevalence rates of 
GI disorders vary widely, with the diff erences proposed to occur 
as a result of genetic, ethnic, cultural, socio-economic, and envi-
ronmental factors plus the respective healthcare policies within 
each country ( 10–14,54 ). With regards to dyspeptic symptoms 
specifi c ally, m odestly a ssociated r isk f actors i nclude s moking, 
nonsteroidal anti-infl a mmatory d rug u sage, a nd  Helicobacter 
pylori status; these factors were not explored in our study ( 14 ). 
Th ird, it has also been shown that over time FGID subtypes do 
change into others although the overall prevalence remains rela-
tively stable ( 55 ). Th is could not be assessed in our study owing 
to its cross-sectional nature. A fourth limitation to be acknowl-
edged is that despite identifying subjects with common doctor-
diagnosed organic GI diseases, as well as those who fulfi lled 
criteria for Rome IV FGIDs, we could potentially have missed 
less common GI conditions. Moreover, we did not have access 
to medical records and neither could we perform any investiga-
tions to confi rm or refute these diagnoses. Previous studies of the 
Rome III criteria for IBS, functional dyspepsia, and functional 
bowel disorders in secondary-care settings have shown that they 
perform modestly when it comes to excluding organic diseases 
( 56–58 ). However, such data have not been available for the gen-
eral population and future studies would benefi t from evaluating 
how the Rome IV performs in excluding organic diseases.
  Finally, our study utilized Internet survey 
methodology, which, despite largely being advantageous 
compared to tradi-tional postal or telephone surveys, may 
still introduce several sources of bias. Th ese issues are 
extensively discussed in the  Supplementary Materials . In 
summary, online surveys are attractive owing to their cost-
eff ectiveness, time convenience, and ability to reach large 
sample sizes. However, owing to our survey methodology, we 
were not able to calculate participation rate, as potential 
subjects in the target demographic categories received e-mail 
notifi cations that a new health survey was avail-able for them, 
but it is unknown how many saw this notice or how many 
responded to it by viewing the consent page. Only those 
who consented to enter the survey could be counted by our 
survey method. Furthermore, despite the annual growth of 
the Internet, between 15 and 20% of USA and UK house-
holds still do not have Internet access (online national 
govern-ment data). Th ere is also the issue of sample bias, 
although we addressed this by performing quota-based 
sampling to gener-ate demographically balanced and 
population representative samples with regards to age, sex, 
and education level. Further, 
 Study Highlights
 WHAT IS CURRENT KNOWLEDGE 
 ✓  Functional gastrointestinal disorders (FGIDs) are currently
defi ned in accordance with the Rome IV diagnostic
questionnaire.
 ✓  Overlapping gastrointestinal symptoms are commonly
reported by subjects with FGIDs.
 ✓  There are no data on the prevalence of Rome IV-diagnosed
FGIDs, the magnitude of their overlap and how this overlap
impacts general health.
 WHAT IS NEW HERE 
 ✓  Roughly, a third of the general adult population in a large
population survey from the USA, Canada, and UK fulfi ls
Rome IV diagnostic criteria for FGIDs, and in a third of
those with FGIDs more than one GI region is involved.
 ✓  There is a direct association between the number of different
GI regions with FGIDs and increasing somatization, worse
quality of life (QOL), and greater healthcare utilization.
 ✓  Importantly, presence of multiple FGIDs is associated
with greater somatization and worse QOL than is seen in
patients with organic GI disease.
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